Oculogica’s concussion test has received FDA clearance and takes some of the guesswork out of concussion assessment and does not require a baseline measurement for comparison. EyeBox uses eye-tracking to provide objective information to aid in the assessment of patients with suspected concussion via a four-minute test. Most concussion assessment methods rely on subjective measures or baseline testing.
The DETECT study showed that the EyeBox had high sensitivity to the presence of concussion and that a negative EyeBox result is consistent with a lack of concussion, thus providing objective data for healthcare providers to aid in the evaluation of patients with suspected TBI. “Looking beyond this milestone, EyeBox has the potential to aid in the diagnosis of other neurological conditions and may benefit researchers developing therapies for TBI and concussion,” said John Leddy, MD, University of Buffalo. “Development of treatments for concussion is challenging because there are few reliable outcome measures. EyeBox may offer one solution to this challenge, providing researchers with an objective oculomotor assessment tool.”